Plain-English translation of NCT05656105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are using a specialized brain imaging technique called PET scanning with a tracer called DPA-714 to look for signs of brain inflammation in people who have long-lasting neurological symptoms after COVID-19 infection. This is an early-phase diagnostic study designed to help doctors understand what might be happening in the brains of people with long COVID. The imaging results from patients will be compared to scans from healthy volunteers to see if there are differences.
Many people experience brain-related symptoms weeks or months after COVID-19 infection, but doctors don't fully understand what is causing these symptoms. This study aims to see if brain inflammation might be part of the problem, which could eventually lead to better treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo brain imaging scans including an MRI and a PET scan with the imaging tracer DPA-714. You will also have blood tests to check your general health and genetic profile. The study will compare your brain images to those of healthy volunteers to look for differences in inflammation. The entire process is diagnostic in nature—researchers are gathering information to understand your condition better, not testing a new treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States